Our suggestion to add biomarkers to the classical components of MetS is in line with the recently updated dyslipidaemia management guideline from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), in which apoB analysis is recommended for cardiovascular risk assessment, particularly in people with high triglycerides, obesity, MetS and diabetes (27). This evidence concerns the gene APOB and diabetes mellitus.